John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
KINGSPORT, Tenn., Feb. 14, 2017 -- ITL Pharma, Inc. (ITL), a LIAS Research Company, today announced awarding of a United States Patent (US 9,526,701) titled: "Sustained Drug Release and Improved Product Stability Using Non-Covalent Particle Coating Methods." This "umbrella" patent provides a novel approach to drug delivery, allowing for extended product stability and controlled release of the API.
TriThroid® (T3, Liothyronine, Na) is the lead product in the pipeline of products utilizing this technology. TriThroid®, now through Phase II clinical trials, provides for once-per-day dosing to fully replace thyroxine (T4) based products and is projected to be especially effective in hypothyroid patients that cannot effectively convert T4 to T3, by providing the active hormone (T3) directly to thyroid hormone target tissues.
"This new Patent is a significant break-through in providing shelf-stable products with sustained drug release and pH dependent PK profiles,” said Dr. Keith R. Latham, ITL's Chief Executive Officer. "This new Patent also provides a critical advance in the delivery of additional drugs in our pipeline including treatments for Cancer, Thyroid, Parkinson's, Alzheimer's and Inflammatory Diseases."
About ITL Pharma
ITL Pharma, Inc. is a privately held US Pharmaceutical company headquartered in Kingsport, Tennessee. Established in VA in 1996 by merger of Inovar Chemicals, Innovative Technologies and Technology Resources, ITL now focuses on new drug discovery and development with 22 new pipeline drugs in 8 therapeutic arenas (www.ITLPharmaceuticals.com).
ITL has now completed Phase II clinical trials on TriThroid®, a sustained release, sustained effects, once-per-day dosing product containing Liothyronine (T3) as the API. This prescription product will replace Levothyroxine (T4) products in a $3.4 Billion market. ITL's vertical integration program anticipates Partnering with companies specializing in market launch and World-Wide distribution and sales.
About LIAS Research
Latham Institute of Advanced Science (LIAS), the parent company for ITL Pharma, provides program integration and management resources to the LIAS Family of Companies. LIAS companies have a pipeline of new prescription drugs and marketed Over the Counter (OTC) products. LIAS CEO, Gina Garland, stated: “We are very pleased with the outstanding progress ITL has made in the treatment of hypothyroidism and other diseases.”
Contact: Dr. Keith R. Latham, CEO ITL Pharma, Inc. 423-444-1474: [email protected]
